Unlocking Opportunities in Medicinal Product Development
For those seeking to develop new drugs without the financial resources and extensive preclinical data required, there exists a compelling opportunity through our Clinical Specials Offering. This unique pathway empowers physicians to prescribe unlicensed medicines, gather valuable treatment data, and potentially justify funding for a full-scale clinical trial under regulatory guidelines.
Enabling Innovation
Under the “Specials” route, physicians can ethically provide unlicensed medicines to patients who lack alternative treatment options. Through this approach, critical treatment data is gathered, forming a basis for further clinical trials and potential market authorization for the medicine.
Early Access Programs
Our expertise extends to guiding clients through the complexities of Early Access Programs (EAP), ensuring compliant access to medicines under development or not yet approved in their country of intended use. This includes providing support for patients who have limited or no alternative treatment options.
Extended Product Life Cycle
Through our Clinical Specials Offering and EAP capabilities, we provide an affordable opportunity for clients to move forward in product development with the added benefit of potentially generating revenue before market authorization.
Cost effective drug development
Clinical Specials, allow entrepreneurial drug developers, a more cost effective and less onerous regulatory pathway for their drug development, reducing the risk in realising their therapeutic target.
